# Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases

> **NCT00606307** · PHASE2 · COMPLETED · sponsor: **Italfarmaco** · enrollment: 29 (actual)

## Conditions studied

- Myeloproliferative Diseases

## Interventions

- **DRUG:** ITF2357

## Key facts

- **NCT ID:** NCT00606307
- **Lead sponsor:** Italfarmaco
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12
- **Primary completion:** 2008-12
- **Final completion:** 2008-12
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2019-12-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00606307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00606307, "Phase IIA Study of the HDAC Inhibitor ITF2357 in Patients With JAK-2 V617F Positive Chronic Myeloproliferative Diseases". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00606307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*